|Articles|April 22, 2011

Enzymotec Signs Krill Deal with India Pharma Company

Enzymotec Ltd. has signed a long term deal to supply krill oil to Lupin Ltd. (Mumbai, India), a leading pharmaceutical company focusing on non-steroidal anti-inflammatory drugs, bacterial infections, and cardiovascular disease.

Enzymotec Ltd. (Migdal HaEmek, Israel) has signed a long term deal to supply krill oil to Lupin Ltd. (Mumbai, India), a leading pharmaceutical company focusing on non-steroidal anti-inflammatory drugs, bacterial infections, and cardiovascular disease.

Lupin is the world’s fifth largest pharmaceutical company, based on subscriptions, says Enzymotec.

A Krill Oil+ product will launch later this year in Indian markets.


Related to this article

SupplySide Global Vitaquest
Live from SupplySide Global 2026, Nutritional Outlook’s Nicholas Jacobus speaks with Michael Anthonavage, VP of innovation at Vitaquest International, about the company’s 2027 consumer trends forecast and how it’s shaping supplement formulation.
Laurentia Bliss
Live from SupplySide Global 2026, Laurentia Bliss talks about new athlete-focused research on Magtein, ThreoTech’s brain-targeted magnesium ingredient, and upcoming innovations like effervescent tablets and gummies.
Klaus Neumann
Live from SupplySide Global 2026, Klaus Neumann talks about Concordix's chewable supplement line spanning beauty and gut-immune health, including BeautyBioti, a Skin & Hair Vitality Complex, and FortiBiotic.